Merck

Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma.

World journal of gastroenterology (2008-05-14)
Toru Ishikawa
RESUMO

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, including Japan. Although the development of imaging modalities has made the early diagnosis of HCC possible, surgically resectable cases are relatively uncommon because of hepatic function reserve and/or an advanced stage at presentation. Several modalities, such as transcatheter arterial chemoembolization, percutaneous ethanol injection, microwave coagulation therapy and radiofrequency ablation are reportedly useful in treating patients with non-resectable disease. However, unfortunately, many HCC patients have tumor recurrence. The overall prognosis of patients with HCC is very poor, and treatment of the advanced form is still problematic. In this article, we review the clinical efficacy and toxicity of enteric-coated tegafur/uracil in the treatment of patients with advanced non-resectable HCC.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Tegafur, ≥98% (HPLC), powder
Fluorouracil impurity C, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Uracil, ≥99.0%
Sigma-Aldrich
Uracil, BioReagent, suitable for cell culture